Company intelligence
Precision Medicine Group
About Precision Medicine Group
We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically need. Our core executive team is anchored to this model, building life science services that address fundamental changes in healthcare that are necessary for health and outcomes improvement.
Verified activity
Signals from Precision Medicine Group
5 published signals
Presence & Recognition
Precision Medicine Group wrapped up the 5th Annual Just Move Challenge, showcasing scenic trails, ocean views, and breathtaking landscapes.
Reported by Precision Medicine Group
Research & Knowledge
Precision Medicine Group announced that former FDA Associate Director Paz Vellanki, MD, PhD, VP of Clinical Development, Oncology, reviewed the DESTINY-Lung04 results and their implications for Enhertu in the first-line treatment setting for HER2-mutated non-small cell lung cancer.
Reported by Precision Medicine Group
Presence & Recognition
Precision Medicine Group Chief Medical Officer Harpreet Singh recently joined pharmaphorum to discuss how Operation TrialBlazer, an HHS initiative, could reshape the IND process.
Reported by Precision Medicine Group
People
Precision Medicine Group is entering the Turkey market and hiring for key roles.
Reported by Mohammad Zahid
Presence & Recognition
Precision Medicine Group has been named as a 2026 MM+M Awards finalist for Market Access Agency of the Year.
Reported by Precision Medicine Group